Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Open Randomized Controlled Trial on the Effectiveness and Tolerability of Trans-resveratrol (derived from Polygonum Cuspidatum Root Extr.) on the Development of CHF in Postmenopausal Women with HTN and Reduced BMD

NCT06828211 is registered in ClinicalTrials.gov with OMNIFARMA LLC as lead sponsor.

NCT NCT06828211
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06828211 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Open Randomized Controlled Trial on the Effectiveness and Tolerability of Trans-resveratrol (derived from Polygonum Cuspidatum Root Extr.) on the Development of CHF in Postmenopausal Women with HTN and Reduced BMD
Lead sponsor
OMNIFARMA LLC
Phase
Not applicable
Overall status
Active, not recruiting
Start date
September 9, 2024
Completion date
March 31, 2025
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arterial hypertension, heart failure, menopause, osteopenia